Generic Name and Formulations:
Natamycin 5%; oph susp; contains benzalkonium chloride 0.02%.
Alcon Laboratories, Inc.
Indications for NATACYN:
Treatment of fungal blepharitis, conjunctivitis, and keratitis due to susceptible organisms including Fusarium solani keratitis.
Keratitis: initially 1 drop in the conjunctival sac at hourly or two-hourly intervals. May reduce to 1 drop 6–8 times daily after the first 3–4 days. Continue for 14–21 days or until resolution. Reduce dose gradually at 4–7 day intervals to assure replicating organism is eliminated. Blepharitis, conjunctivitis: less frequent initial dosage (4–6 daily applications) may be sufficient.
Reevaluate if no improvement after 7–10 days. Monitor at least twice weekly; discontinue if drug toxicity occurs. Pregnancy (Cat. C). Nursing mothers.
Conjunctival chemosis and hyperemia.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking